H A Liebman

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi request reprint Secondary immune thrombocytopenic purpura
    Howard A Liebman
    University of Southern California Keck School of Medicine, Los Angeles, California, USA
    Curr Opin Hematol 14:557-73. 2007
  2. doi request reprint Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics
    Howard A Liebman
    Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Hematology Am Soc Hematol Educ Program 2011:384-90. 2011
  3. ncbi request reprint Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor
    Howard A Liebman
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Kenneth Norris Jr Cancer Center, Rm 3466, 1441 Eastlake Ave, Los Angeles, CA 90033, USA
    Thromb Res 111:235-8. 2003
  4. ncbi request reprint Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance
    Casey L O'Connell
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    J Clin Oncol 24:4928-32. 2006
  5. ncbi request reprint Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient
    Howard A Liebman
    Keck School of Medicine, University of Southern California, Los Angeles 90033, USA
    Cancer Control 12:11-6. 2005
  6. ncbi request reprint Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII
    H A Liebman
    University of Southern California School of Medicine, Division of Hematology, Los Angeles, California 90033, USA
    Am J Hematol 63:109-13. 2000
  7. ncbi request reprint The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease
    H A Liebman
    Division of Hematology, Department of Medicine, University of Southern California School of Medicine, Los Angeles, California, USA
    Gastroenterology 115:830-4. 1998
  8. doi request reprint Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft thrombosis or thrombocytopenia
    Tamas Alexy
    Department of Physiology and Biophysics, Los Angeles County University of Southern California USC Medical Center, USC University Hospital, Los Angeles, California, USA
    J Vasc Surg 48:377-81. 2008
  9. ncbi request reprint Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance
    H A Liebman
    Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033, USA
    Br J Haematol 95:550-3. 1996
  10. doi request reprint Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders
    Howard A Liebman
    Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Semin Hematol 46:S33-6. 2009

Collaborators

Detail Information

Publications28

  1. ncbi request reprint Secondary immune thrombocytopenic purpura
    Howard A Liebman
    University of Southern California Keck School of Medicine, Los Angeles, California, USA
    Curr Opin Hematol 14:557-73. 2007
    ..The guidelines did not address thrombocytopenia resulting from autoimmune disorders or chronic infections such as Helicobacter pylori, hepatitis C virus or HIV...
  2. doi request reprint Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics
    Howard A Liebman
    Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Hematology Am Soc Hematol Educ Program 2011:384-90. 2011
    ..In this article, we review the current data on the efficacy and safety of thrombopoietin receptor agonists and discuss other therapies as well as diagnostic work up of ITP...
  3. ncbi request reprint Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor
    Howard A Liebman
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Kenneth Norris Jr Cancer Center, Rm 3466, 1441 Eastlake Ave, Los Angeles, CA 90033, USA
    Thromb Res 111:235-8. 2003
    ..We propose that thrombosis in PNH results from increased tissue factor expression by complement injured CD55- and CD59-deficient monocytes and macrophages...
  4. ncbi request reprint Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance
    Casey L O'Connell
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    J Clin Oncol 24:4928-32. 2006
    ..We hypothesized that these patients had signs or symptoms suggestive of PE that may have been overlooked by their health care providers...
  5. ncbi request reprint Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient
    Howard A Liebman
    Keck School of Medicine, University of Southern California, Los Angeles 90033, USA
    Cancer Control 12:11-6. 2005
  6. ncbi request reprint Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIII
    H A Liebman
    University of Southern California School of Medicine, Division of Hematology, Los Angeles, California 90033, USA
    Am J Hematol 63:109-13. 2000
    ..The results of this limited series indicate that rFVIIa is an effective means of managing life-threatening abdominal bleeding in individuals with hemophilia or acquired antibodies to factor VIII...
  7. ncbi request reprint The factor V Leiden mutation increases the risk of venous thrombosis in patients with inflammatory bowel disease
    H A Liebman
    Division of Hematology, Department of Medicine, University of Southern California School of Medicine, Los Angeles, California, USA
    Gastroenterology 115:830-4. 1998
    ..The aim of this study was to determine the incidence and possible association of the factor V Leiden mutation with the development of thrombosis in patients with IBD...
  8. doi request reprint Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft thrombosis or thrombocytopenia
    Tamas Alexy
    Department of Physiology and Biophysics, Los Angeles County University of Southern California USC Medical Center, USC University Hospital, Los Angeles, California, USA
    J Vasc Surg 48:377-81. 2008
    ..A prospective study was conducted to monitor the development and function of platelet factor 4 (PF4)/heparin antibodies after infrainguinal bypass procedures and to evaluate their clinical significance in early graft occlusion...
  9. ncbi request reprint Evaluation of a tissue factor dependent factor V assay to detect factor V Leiden: demonstration of high sensitivity and specificity for a generally applicable assay for activated protein C resistance
    H A Liebman
    Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033, USA
    Br J Haematol 95:550-3. 1996
    ..The single-stage tissue factor dependent factor V assay is a highly sensitive and generally applicable assay for APCR...
  10. doi request reprint Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders
    Howard A Liebman
    Jane Anne Nohl Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    Semin Hematol 46:S33-6. 2009
    ....
  11. doi request reprint Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond
    Casey L O'Connell
    Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Expert Rev Hematol 1:175-82. 2008
    ....
  12. ncbi request reprint Progressive prothrombotic state in women with advancing HIV disease
    Alexandra M Levine
    Department of Medicine, Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA
    J Acquir Immune Defic Syndr 42:572-7. 2006
    ..HIV-infected patients are at increased risk for venous thrombotic events (VTEs). We sought to determine if advancing stages of HIV were associated with coagulation abnormalities that could predispose to VTE...
  13. ncbi request reprint Heparin-induced thrombocytopenia: diagnosis and management
    Howard A Liebman
    University of Southern California Keck School of Medicine, Jane Anne Nohl Division of Hematology, Center for the Study of Blood Diseases, Los Angeles, CA, USA
    Vascular 16:S71-6. 2008
    ..Owing to the high risk of thrombosis associated with HIT, antithrombotic therapy with direct thrombin inhibitors (lepirudin or argatroban) should be started when serologic assays confirm clinical suspicion...
  14. ncbi request reprint Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment
    Douglas E Sutherland
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Am J Hematol 72:43-52. 2003
    ..The purpose of this review is to examine our current understanding of thrombosis as a complication of cancer and cancer therapy. The review includes a discussion of the epidemiology, pathophysiology, diagnosis and treatment...
  15. ncbi request reprint Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura
    Sandeep K Rajan
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    Br J Haematol 129:818-24. 2005
    ..001 compared with HCV-TP). HCV infection can be associated with significant thrombocytopenia and appears to be a distinct clinical entity...
  16. pmc Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy
    Jeffrey I Zwicker
    Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Clin Cancer Res 15:6830-40. 2009
    ..We evaluated the hypothesis that tumor-derived tissue factor-bearing microparticles in plasma contribute to cancer-associated thrombosis...
  17. ncbi request reprint Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation
    Ilene C Weitz
    Division of Hematology, Kenneth Norris Jr Comprehensive Cancer Center, California Cancer Medical Center, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    Thromb Haemost 88:213-20. 2002
    ....
  18. doi request reprint Approach to the treatment, characterization and diagnosis of an acquired auto-antibody directed against factors prothrombin, factor X and factor IX: a case report and review of the literature
    L Rochanda
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    Haemophilia 18:102-7. 2012
    ....
  19. ncbi request reprint Anticoagulation is an effective treatment for aortic mural thrombi
    Michael E Bowdish
    Division of Vascular Surgery, Department of Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    J Vasc Surg 36:713-9. 2002
    ..Aortic mural thrombi (AMT) in the absence of aortic disease are rare. The appropriate indications and the efficacy of surgical thrombectomy, thrombolysis, and systemic anticoagulation remain controversial...
  20. pmc Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism
    David A Manly
    Division of Hematology Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7035, USA
    Thromb Res 125:511-2. 2010
    ..7+/-3.8 pg/mL vs 0.6+/-0.4 pg/mL, p<0.05). Further prospective studies are required to determine if levels of MP TF activity may be a useful biomarker to identify patients at increased risk for VTE...
  21. ncbi request reprint Didanosine in the treatment of AIDS and AIDS-related complex: a critical appraisal of the dose and frequency of administration
    H A Liebman
    Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033
    Clin Infect Dis 16:S52-8. 1993
    ..d) for extended periods. A review of these studies suggests that a twice-daily schedule of didanosine administration at a daily dose of 5-10 mg/(kg.d) is safe and is associated with significant antiretroviral activity in vivo...
  22. doi request reprint Unsuspected pulmonary emboli adversely impact survival in patients with cancer undergoing routine staging multi-row detector computed tomography scanning
    C O'CONNELL
    Jane Anne Nohl Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    J Thromb Haemost 9:305-11. 2011
    ....
  23. ncbi request reprint Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism
    Vinod Pullarkat
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine and the Kenneth Norris Jr Cancer Hospital, Los Angeles, CA, USA
    Br J Haematol 118:1166-9. 2002
    ..Detection of the lupus anticoagulant in patients with AIHA identifies individuals at significantly increased risk for VTE. Future studies should address the role of prophylactic anticoagulation in patients with AIHA...
  24. ncbi request reprint The role of oral anticoagulants in tumor biology
    Ilene C Weitz
    Division of Hematology, Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Semin Thromb Hemost 33:695-8. 2007
    ....
  25. ncbi request reprint Rituximab treatment for resistant antiphospholipid syndrome
    Elyse Rubenstein
    Division of Rheumatology and Division of Hematology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA
    J Rheumatol 33:355-7. 2006
    ..Since rituximab infusion, all the patients have had stable platelet counts and no further episodes of bleeding or thromboses...
  26. pmc Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)
    K Arzoo
    Department of Medicine, University of Southern California, Keck School of Medicine, Los Angeles, California 90033, USA
    Ann Rheum Dis 61:922-4. 2002
    ..Rituximab, a chimeric monoclonal anti-CD20 antibody, has recently been used for the treatment of refractory antibody mediated autoimmune diseases such as immune mediated thrombocytopenia and haemolytic anaemia...
  27. ncbi request reprint Acquired bleeding disorder in a patient with malignant lymphoma: antibody-mediated prothrombin deficiency
    E S Lee
    Division of Hematology, Department of Medicine, University of Southern California School of Medicine, Los Angeles, California, USA
    Cancer 91:636-41. 2001
    ..An acquired prothrombin deficiency has not been reported previously in association with a malignancy, and this patient represents the first such documented case...
  28. doi request reprint Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
    David J Kuter
    Massachusetts General Hospital, Boston, MA 02114, USA
    Lancet 371:395-403. 2008
    ..We assessed the long-term administration of romiplostim in splenectomised and non-splenectomised patients with ITP...